In Sudan, the first-ever double-blind, randomized clinical trial for fungal mycetoma is ongoing and had enrolled 101 patients by January 2020. The primary objective of the study is to demonstrate the superiority of the new chemical entity fosravuconazole over the current standard treatment, itraconazole. The study’s targeted enrollment of 165 patients should be reached by the end of 2020.
8-11 February 2020
- Presentations on mycetoma and leishmaniasis
Health Policy Watch [10 January 2020]
“Mental health – among the ‘most neglected’ of neglected tropical disease issues, says DNDi scientist”
The Telegraph [25 September 2019]
“A glimmer of hope in the fight against a flesh-eating ‘silent killer'”
by Hay R, Denning DW, Bonifaz A, Queiroz-Telles F, Beer K, Bustamante B, Chakrabarti A, Chavez-Lopez MG, Chiller T, Cornet M, Estrada R, Estrada-Chavez G, Fahal A, Gomez BL, Li R, Mahabeer Y, Mosam A, Soavina Ramarozatovo L, Rakoto Andrianarivelo M, Rapelanoro Rabenja F, van de Sande W, Zijlstra EE.
Tropical Medicine and Infectious Diseases, September 2019
16-20 September 2019
- DNDi – one symposium on cutaneous leishmaniasis and one on mycetoma
- Nathalie Strub-Wourgaft, NTD Director – panel discussion on the future of research and development, satellite symposium on sleeping sickness
Better than boiling oil or amputation? Stories behind the treatment needs of two of the world’s most neglected tropical diseases, cutaneous leishmaniasis and mycetoma
16 September 2019
- Join us on the sidelines of the 2019 European Congress for Tropical Medicine and International Health for the engaging stories of Pip Stewart, a British adventurer who contracted CL on a record-breaking paddling trip in the Amazon, and two researchers working on the first-ever clinical trial for a fungal mycetoma treatment, Dr Borna Nyaoke, a physician and clinical researcher from DNDi based in Nairobi, Kenya, and Dr Sahar Bakhiet, a microbiologist at the Mycetoma Research Centre in Khartoum, Sudan who works with communities affected by mycetoma.
The first-ever double-blind, randomized clinical trial for fungal mycetoma, underway in Sudan, had enrolled 84 patients by January 2019, the threshold for interim analysis. The primary objective of the study is to demonstrate the superiority of fosravuconazole over the current standard, itraconazole.
15-17 February 2019
- DNDi – co-sponsoring the event and presentation on the open innovation project MycetOS
- Monique Wasuna, Director DNDi Africa – chair for a session on international collaboration for mycetoma
- Nathalie Strub-Wourgaft, NTD Director – session on the way forward for mycetoma
67th Annual Meeting
28 October – 1 November 2018
New Orleans, USA
- Nathalie Strub-Wourgaft, NTD Director – presentation on fexinidazole in a symposium on sleeping sickness elimination
- Colin Forsyth, Chagas Epidemiologist, Sergio Sosa Estani, Head of Chagas Clinical Programme, Eric Chatelain, Head of Drug Discovery Programme – symposium on screening and diagnosis of Chagas disease
- Poster and oral presentations on sleeping sickness, visceral leishmaniasis, Chagas, onchocerciasis, and mycetoma
Former DNDi Medical Director Dr Nathalie Strub-Wourgaft takes over leadership of NTD programme
DNDi is pleased to announce the appointment of Dr Nathalie Strub-Wourgaft as the new Director of Neglected Tropical Diseases. She will assume her new role as NTD Director and member of DNDi’s Executive Team as of 1 July 2018.
3-4 October 2018
- DNDi – sessions on the LEAP Platform activities, policy, the AfriKADIA project, PKDL, and capacity strengthening
by Lim W, Melse Y, Konings M, Phat Duong H, Eadie K, Laleu B, Perry B, Todd M, Ioset J-R, and van de Sande W.
PLOS Neglected Tropical Diseases, April 2018
30 June-4 July 2018
Amsterdam, the Netherlands
Ed Zijlstra, Senior Consultant, DNDi – session on mycetoma